Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cheno Effect on Transit in Health and IBS-C (Chenotransit)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00912301
Recruitment Status : Completed
First Posted : June 3, 2009
Results First Posted : July 2, 2012
Last Update Posted : July 2, 2012
Sponsor:
Collaborators:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Center for Research Resources (NCRR)
Information provided by:
Mayo Clinic

Tracking Information
First Submitted Date  ICMJE May 29, 2009
First Posted Date  ICMJE June 3, 2009
Results First Submitted Date  ICMJE May 29, 2012
Results First Posted Date  ICMJE July 2, 2012
Last Update Posted Date July 2, 2012
Study Start Date  ICMJE April 2009
Actual Primary Completion Date November 2009   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 29, 2012)
Colonic Geometric Center at 24 Hours (GC24) [ Time Frame: after 4 days of treatment ]
The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.
Original Primary Outcome Measures  ICMJE
 (submitted: June 2, 2009)
Colonic Geometric Center at 24 Hours (GC24) [ Time Frame: after 4 days of treatment ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 29, 2012)
  • Colonic Transit at 48 Hours (GC48) [ Time Frame: after 4 days of treatment ]
    The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.
  • Ascending Colon Emptying (AC t_1/2) [ Time Frame: after 4 days' treatment ]
  • Stool Consistency [ Time Frame: after 4 days' treatment ]
    The subjects rated their stool consistency using the Bristol Stool Scale. The Bristol Stool Scale is a medical aid designed to classify the form of human feces into seven categories or types. Types 1 and 2 indicate constipation with 3 and 4 being the "ideal stools" especially the latter, as they are the easiest to defecate, and 5-7 tending towards diarrhea.
  • Colonic Filling at 6 Hours [ Time Frame: after 4 days' treatment ]
    Percent of the radio-labeled meal that reached the colon at 6 hours, indirectly reflecting small bowel transit time.
Original Secondary Outcome Measures  ICMJE
 (submitted: June 2, 2009)
  • Colonic transit GC48 h [ Time Frame: after 4 days of treatment ]
  • Ascending colon emptying T1/2 [ Time Frame: after 4 days' treatment ]
  • Stool Consistency [ Time Frame: after 4 days' treatment ]
  • Colonic Filling at 6 Hours [ Time Frame: after 4 days' treatment ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Cheno Effect on Transit in Health and IBS-C
Official Title  ICMJE Effect of Chenodeoxycholic Acid on Gastrointestinal Transit and Colonic Functions in Health and Constipation-predominant Irritable Bowel Syndrome (IBS-C)
Brief Summary The study hypothesis is that the naturally occurring bile acid, chenodeoxycholic acid, induces acceleration of colonic transit in health and in patients with constipation-predominant Irritable Bowel Syndrome (IBS-C).
Detailed Description

Hypothesis: A hydrophobic di-alpha hydroxy bile salt, sodium chenodeoxycholate (CDC), delivered in a delayed release capsule to the ileocolonic region of the colon induces acceleration of colonic transit in patients with constipation-predominant IBS.

Methods: We shall study 36 patients with IBS-C, aged 18-65 years, and each treatment group will be balanced on gender and Body Mass Index (BMI) in the randomization. All patients will be assessed for symptoms of functional gastrointestinal disorder or psychological disturbance will be characterized in a standard fashion with questionnaires (Talley et al 1989), the Psychosomatic Symptom Checklist (SCL-90) and the Hospital Anxiety and Depression Inventory [HAD (Zigmond and Snaith 1983)]. With appropriate consent, a venous blood sample will be obtained from each participant for DNA extraction. Fasting Serum 7alpha-hydroxy-4-cholesten-3-one (7alpha-CHO) will be measured in all to ensure they do not have evidence of asymptomatic bile acid malabsorption. The normal range in our lab is <61 ng/mL.

Experimental design: A randomized, double blind, placebo controlled, dose-response parallel group design, with concealed allocation. Participants will undergo an initial baseline colonic transit for 24 hours to obtain Colonic Geometric Center (GC24). Sodium chenodeoxycholate (CDC) will be delivered to the ileocolonic region to assess ascending colon and whole colonic transit in participants with IBS-C; 12 participants per group will be randomized to placebo, 0.5 or 1 gram CDC each for a period of 4 days with the transit study conducted during the last 48 hours of drug ingestion. The CDC will be placed in gelatin capsules that are coated with methacrylate (EUDRAGIT-L®), a pH-sensitive polymer that will result in release of the active ingredient in the terminal ileum.

Experimental procedure: At standardized times (hourly for first 8 hours, and at 12, 24 and 48 h), dual gamma camera scans will be obtained to measure ascending colon and overall colonic transit. Patients will fill daily diaries to evaluate stool, frequency, consistency and ease of passage.

Gastrointestinal and Colonic Transit: A validated scintigraphic method to measure gastric, small bowel, and colonic transit will be used. A methacrylate-coated capsule dissolves in the alkaline pH of the distal ileum to release 111In-labeled activated charcoal particles to evaluate colonic transit on sequential scans. Meanwhile, orally ingested 99 mTc-labeled egg meal allows measurement of gastric and small bowel transit. (Technetium [99mTc] sestamibi (trade name Cardiolite) is a pharmaceutical agent used in nuclear medicine imaging.) We have previously shown that the gastric emptying (GE) at 2 and 4 hours, colonic filling (CF) at 6 hours, and colonic geometric center (GC, weighted average of isotopic counts) in colon at 4, 24 and 48 hours provide excellent summaries of gastric emptying and colonic transit with similar diagnostic accuracy as more detailed, costly, and time-consuming analyses. The normal values for these parameters have been previously published (Cremonini et al).

Scintigraphic gastric emptying and intestinal/colonic transit analysis: A variable region of interest program will be used to measure transit, as in previous studies from our lab. Radioisotope content in each region (gastric, ascending, transverse, descending, rectosigmoid) will be corrected for decay and tissue attenuation or depth.

Anticipated Result: CDC will accelerate whole colonic transit and loosen stool form in patients with constipation predominant IBS.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Constipation-predominant Irritable Bowel Syndrome
Intervention  ICMJE
  • Drug: Sodium chenodeoxycholate (NaCDC)
    500 or 1000 milligrams NaCDC per day each for a period of 4 days
    Other Name: Chenodiol
  • Other: Placebo
    Placebo capsules with identical appearance to the study drug were prepared by the Mayo Clinic research pharmacy.
Study Arms  ICMJE
  • Experimental: NaCDC 500 mg
    Participants randomized to this arm received 500 mg NaCDC per day for 4 days.
    Intervention: Drug: Sodium chenodeoxycholate (NaCDC)
  • Experimental: NaCDC 1000 mg
    Participants randomized to this arm received 1000 mg NaCDC per day for 4 days.
    Intervention: Drug: Sodium chenodeoxycholate (NaCDC)
  • Placebo Comparator: Placebo
    Participants randomized to this arm received a placebo capsule each day for 4 days.
    Intervention: Other: Placebo
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: May 29, 2012)
36
Original Estimated Enrollment  ICMJE
 (submitted: June 2, 2009)
120
Actual Study Completion Date  ICMJE December 2009
Actual Primary Completion Date November 2009   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Healthy volunteers:

  • Age (yr) 18-65
  • Gender (F:M)3.5 :1
  • Bowel Disease Questionnaire (BDQ) - IBS symptoms negative by Rome III criteria
  • Hospital Anxiety/Depression score <8

IBS patients:

  • Age (yr) 18-65
  • Gender (F:M) 5 :1
  • BDQ - IBS symptoms: positive by Rome III criteria
  • Hospital Anxiety/Depression score: No restrictions

Exclusion Criteria:

  • Abdominal surgery (except appendectomy or cholecystectomy)
  • GI medications during the 48h prior to transit measurement
  • Aspartate/Alanine transaminases >2 X Upper Limit of Normal (ULN)
  • Other Medications except stable doses of estrogen, thyroid, low dose antidepressants of the dopaminergic or serotonergic class
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00912301
Other Study ID Numbers  ICMJE 08-001003
R01DK054681 ( U.S. NIH Grant/Contract )
R01DK079866 ( U.S. NIH Grant/Contract )
UL1RR024150 ( U.S. NIH Grant/Contract )
1RC1DK086182 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Michael Camilleri, M.D., Mayo Clinic
Study Sponsor  ICMJE Mayo Clinic
Collaborators  ICMJE
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • National Center for Research Resources (NCRR)
Investigators  ICMJE
Principal Investigator: Michael L. Camilleri, M.D. Mayo Clinic
PRS Account Mayo Clinic
Verification Date May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP